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Long-term cardiovascular morbidity is increasingly observed in chemotherapy-treated testicular cancer survivors, but little is known of
early sub-clinical changes in cardiac function. We prospectively evaluated cardiac function in testicular cancer patients by
echocardiography. Systolic (Wall Motion Score Index) and diastolic (E/A-ratio and Tissue Velocity Imaging (TVI)) parameters, and
serum levels of N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) were assessed before the start of chemotherapy and 1 year
later. Echocardiography data were compared with an age-matched group of healthy controls. Forty-two patients treated with
bleomycin, etoposide and cisplatin were evaluated (median age 27 years, range 18–50). Systolic function and E/A-ratio did
not change, whereas the median TVI decreased (12.0 vs 10.0cms
 1; P¼0.002). Median levels of NT-proBNP increased
(5 vs 18pmoll
 1, P¼0.034). Compared with controls, TVI before the start of chemotherapy was not significantly different. In
conclusion, we found that at a median of 10 months after cisplatin-based treatment for testicular cancer, TVI decreased significantly,
indicating a deterioration of diastolic cardiac function. Serum levels of NT-proBNP increased. The prognostic significance of these
changes for future cardiovascular morbidity is not clear.
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Testicular cancer (TC), the most frequent type of solid malignancy
in young male adults, has become a highly curable disease since
the late 1970s with the introduction of cisplatin-containing
chemotherapy regimens. In the growing population of TC
survivors, the occurrence of long-term treatment-induced organ
damage is increasingly recognised as an important cause of
morbidity (Feldman et al, 2008). Compared with the general
population, long-term TC survivors have a higher incidence of
second malignant neoplasms and cardiovascular disease (Meinardi
et al, 2000; Strumberg et al, 2002; Huddart et al, 2003; van den
Belt-Dusebout et al, 2007).
In earlier studies, investigating cardiac morbidity in long-term
TC survivors at a median of 7–14 years after chemotherapy, we
found diastolic dysfunction in 17–33% of patients (Meinardi et al,
2000; Nuver et al, 2005a). Sub-clinical signs of vascular toxicity
were found in a prospective study in TC patients 10 weeks after
cisplatin-based chemotherapy (Nuver et al, 2005b). Still, little is
known about (sub-) acute cardiotoxicity in TC patients, and to our
knowledge, no studies report on early cardiotoxicity. Furthermore,
it is not established which parameters are useful in the early
assessment of cardiac damage.
In addition to obtaining insight in the extent and timing of
cardiac complications of chemotherapeutic treatment for TC,
evaluation of parameters for early (sub-clinical) cardiac dysfunc-
tion may enable the identification of patients who are at risk for
future cardiovascular events. Echocardiography is a convenient
and frequently used method to assess cardiac function, enabling
evaluation of both systolic and diastolic function parameters.
Biochemical markers can also be used to evaluate cardiac status.
N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) is pro-
duced by ventricular cells in response to increased mechanical load
and wall stretch. Plasma levels are used as a prognostic indicator in
different stages and causes of cardiac disease (Doust et al, 2005).
However, its role in detecting chemotherapy-induced cardiac
morbidity has not been established yet (Bryant et al, 2007; Ekstein
et al, 2007).
In this prospective cohort study, we investigated echocardio-
graphic and biochemical changes before and at 1 year after the
start of cisplatin-containing chemotherapy for disseminated TC.
PATIENTS AND METHODS
Patients
All consecutive patients with disseminated TC, scheduled to
receive cisplatin-containing chemotherapy as first-line therapy
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sat the University Medical Centre Groningen, the Netherlands,
between December 2000 and October 2004 were asked to parti-
cipate in a study investigating the chemotherapy-induced acute
cardiovascular toxicity (Nuver et al, 2005b). Exclusion criteria
were extra-pulmonary visceral metastases, earlier radiotherapy,
pre-treatment history of cardiac disease, use of erythropoietin and
an age older than 55 years at the start of chemotherapy. The study
was approved by the local ethics committee and written informed
consent was obtained from all participants.
After orchidectomy, all patients received three or four three-
weekly courses of combination chemotherapy consisting of
bleomycin (30mg on days 2, 8 and 15), etoposide (100mgm
–2
on days 1–5 of each course) and cisplatin (20mgm
–2on days 1–5
of each course). Patients were admitted to the hospital for
hydration with 3l of 0.9% NaCL per day during the first 6 days
of each course. All patients received dexamethason and odansetron
as standard anti-emetic therapy.
Reference data were obtained from healthy male siblings
of adult childhood cancer survivors, who had participated as
control subjects in a cross-sectional study on late cardio-
vascular sequelae of treatment for childhood cancer. Out of
these healthy male siblings, a control group was selected with a
comparable median age as the TC patients. Measurements in
the controls were carried out under similar circumstances and
methods.
Measurements
Measurements were done within 1 week before the start of chemo-
therapy and B1 year after the completion of treatment.
Echocardiography
Echocardiography was carried out by a skilled technician at the
same laboratory using conventional equipment (General Electrical
VIVID 7 system, Horton, Norway, with a 2.5MHz probe) and
consisted of two-dimensional echocardiography, colour-flow
mapping and, since 2002, tissue velocity imaging (TVI) (Cheitlin
et al, 2003). Left ventricular end-diastolic dimension (LVEDD,
normal 36–54mm), left ventricular end-systolic dimension
(LVESD, normal 23–40mm), posterior and septal wall thickness
(normal 7–11mm) were measured on M-mode recordings
obtained in the standard left ventricular parasternal long-axis
view. The parasternal, transverse and longitudinal dimensions of
the left atrium were attained.
For the analysis of systolic function, the left ventricle was
divided into 16 segments. Each segment was visually scored
between 1 and 4 (1¼normokinesia, 2¼hypokinesia, 3¼akinesia,
4¼dyskinesia). The wall motion score index (WMSI) was the
mean score for all the analysed segments. A WMSI of 1.00 was
considered normal.
Diastolic function measurements included the mitral valve
inflow velocities in early (E) and late (atrial; A) diastole
(E/A-ratio, normal 41.00) and tissue velocity imaging of early
diastole (TVI Et). Tissue velocity imaging of early diastole was the
mean of measurements at the septal, lateral, inferior and anterior
mitral annulus (normal 48.0cms
–1; decreases indicate deteriora-
tion of diastolic function). In addition E/E0 was calculated from the
peak E velocity and the mean TVI Et (normal o15; increases
reflect declines in diastolic function; E/E0 415 is considered as
diastolic dysfunction). E/E0 is currently regarded as a sensitive
method for assessing diastolic heart failure (Paulus et al, 2007).
NT-proBNP
N-Terminal pro-Brain Natriuretic Peptide (lower limit of detec-
tion 5.0pmoll
–1; normal value o14.75pmoll
–1) was measured in
plasma using an immunoassay (Roche Diagnostics, Mannheim,
Germany) from samples that were drawn concomitant with the
echocardiographic recordings.
Cardiovascular risk factors (CRFs)
Cardiovascular risk factors were estimated before the start of
chemotherapy. Hypercholesterolaemia was defined as a fasting
level of cholesterol 46.5mmoll
–1; diabetes mellitus as a fasting
level of glucose 47.0mmoll
–1. Obesity as body mass index (BMI)
427.8kgm
–2. Blood pressure (BP) was estimated as a single
recording on one arm in supine position in a quiet room after a
minimal rest period of 10min. Furthermore, an ambulatory BP
device (Spacelab 90207; Spacelabs Inc., Redmond, WA, USA) was
used to document BP every 30min during a 24h period. The
control subjects had a single BP recording.
The criteria for hypertension were defined as a mean 24h BP
4135/85mmHg, a single BP 4145/95mmHg and/or the use of
anti-hypertensive medication.
Statistics
Statistical analyses were carried out in the statistical software
package SPSS for Windows version 14.0 (SPSS Inc., Chicago, IL,
USA). For comparisons the w
2-test and the non-parametric Mann–
Whitney test were used. To calculate changes within a patient the
Wilcoxon signed-rank test was used on the paired samples in those
patients where both variables were available. Regressions were
calculated with Spearman’s correlation. Two-sided P-values p0.05
were considered to indicate significant differences.
Post-hoc power analysis showed that, with a power of 80% and a
two-sided significance level (alpha) of Po0.05, a 3.3% change in
TVI Et could be detected in 19 patients, with a correlation coefficient
between two measurements under equal circumstances of X0.75
and variation-coefficient for TVI Et of 7.1% (Kowalski et al, 2001).
RESULTS
Patients
Between December 2000 and October 2004, 65 TC patients were
enrolled in the study (Nuver et al, 2005b). In 54 of these 65 patients
an echocardiogram was performed before the start of chemo-
therapy. Twelve out of 54 (22%) patients received no echo-
cardiogram after the completion of cisplatin-based chemotherapy,
because of the following reasons: death (n¼1), progressive disease
(n¼1) or logistic reasons (data not evaluable n¼3; moved out of
referral area n¼1; not performed n¼6). Therefore, 42 patients
underwent an echocardiogram before and within 1 year after the
completion of cancer treatment. The baseline characteristics like
age, disease status and echocardiographic parameters of the
patients (n¼12) who did not receive an echocardiogram after
treatment were not different from the patients that completed two
echocardiographic evaluations (data not shown).
Baseline characteristics of the 42 patients with two echocardio-
graphic evaluations are shown in Table 1. Of the 42 evaluable
patients, 12 had pulmonary metastases and one underwent
thoracotomy for resection of pulmonary lesions after the comple-
tion of chemotherapy.
The control group consisted of 42 healthy males, whose median
age was 28 years (Table 2); none of them was known to have
co-morbidity.
Echocardiography
Echocardiography before treatment Before the start of treatment,
one out of 33 patients had a WMSI 41.00 (3.0%). Four out of
41 patients had abnormal wall motion (all local hypokinesia;
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s9.8%). Three out of 42 had valve dysfunction (pulmonal (n¼2)
and tricuspid valve insufficiency (n¼1); 7.1%).
The E/A-ratio was o1.00 in 8 out of 42 patients (19.0%); 1 out of
22 assessed patients had a TVI Et o8.0cms
–1 (4.5%). None of
these 22 patients had an E/E0 415. Median values and ranges are
summarised in Tables 2 and 3.
Of the controls, 1 out of 42 had had a WMSI >1.00. One out of 42
had an E/A radion o1.00; 1 out of 42 had a TVI Et mean
o8.00cms
–1. For median values and ranges, see Table 2.
The median WMSI and TVI Et in patients and the controls was
not different (P¼0.259; P¼0.713), whereas the median E/A-ratio
was higher in the controls (Po0.0001, Table 2).
Echocardiography after treatment At a median of 10 months after
the completion of treatment, 4 out of 28 patients had a WMSI
41.00 (14.3%). Seven out of 40 patients had wall motion
abnormalities (17.5%, local and/or diffuse hypo- and akinesia).
The E/A-ratio was o1.00 in 7 out of 41 patients (17.1%); 2 out of
25 assessed patients had a TVI Et o8cms
–1 (8.0%). None of the
25 patients had an E/E0 415.
Changes in echocardiography before and after treatment Cardiac
dimensions and the median WMSI did not change during the
year after treatment (Table 3). The percentage of patients with
wall motion abnormalities did not change (9.8 vs 17.5%;
P¼0.309), whereas the number of patients with a WMSI 41.00
increased (P¼0.01). The seven patients with post-treatment wall
motion abnormalities included the four patients with pre-
treatment abnormalities; all of them had deterioration of wall
motion abnormalities. Two of them developed pulmonary
embolisms during the treatment (Nuver et al, 2005b). Three
patients newly developed wall motion abnormalities at 1 year
after treatment; one had a myocardial infarction during
chemotherapy.
Paired observations of the TVI Et were available in 19 TC
patients. The median TVI Et decreased significantly after treat-
ment (P¼0.002; Figure 1); the median E/A-ratio did not change
(see Table 3). In addition, the median E/E0 increased (P¼0.002;
Table 3).
Age correlated with pre-treatment E/A-ratio (R¼ 0.50;
P¼0.001), but not with pre-treatment TVI Et (R¼ 0.27;
P¼0.219) or D TVI Et (difference between pre- and post-treatment
TVI Et; R¼0.21; P¼0.382).
NT pro-BNP
The median level of NT-proBNP increased significantly (n¼32;
pretreatment 5pmoll
–1 (range o5–242); post-treatment
18pmoll
–1 (range o5–114); P¼0.034, Figure 2). One extreme
Table 2 Baseline characteristics and cardiac parameters of testicular
cancer patients and healthy control subjects
Patients Controls
n
a
Median
(range) n
Median
(range) P-value
b
Age 42 27 (18–50) 42 28 (18–42) 0.907
Systolic blood pressure 30 133 (110–180) 42 115 (98–156) o0.0001
Diastolic blood pressure 30 80 (50–130) 42 79 (60–96) 0.237
Body mass index 30 24 (19–38) 42 25 (19–31) 0.656
TVI Et 22 12.0 (7–19) 42 12.4 (9–15) 0.713
E/A ratio 42 1.38 (0.73–2.84) 42 1.69 (1.02–2.66) o0.0001
WMSI 33 1.00 (1.00–1.23) 42 1.00 (1.00) 0.259
aNumber of patients in which the respective parameters were available.
bMann–Whitney test.
Table 3 Echocardiographic parameters of testicular cancer patients
before and after chemotherapeutic treatment
Before After
n
a
Median
(range) n
Median
(range) P-value
b
Systolic parameters
WMSI 33 1.00 (1.00–1.23) 28 1.00 (0.81–1.44) 0.273
Structural dimensions
Septum (mm) 42 10 (6–12) 41 10 (7–14) 0.427
Posterior wall (mm) 41 10 (8–12) 41 9 (7–11) 0.309
LVEDD (mm) 42 50 (41–57) 41 50 (41–55) 0.861
LVESD (mm) 41 32 (18–42) 41 32 (21–41) 0.741
LA parasternal (mm) 42 35 (25–42) 41 35 (25–46) 0.198
LA length (mm) 40 57 (44–69) 41 58 (46–69) 0.764
LA transverse (mm) 24 38 (29–45) 31 39 (29–52) 0.267
Heartbeat (bpm) 34 70 (48–105) 31 66 (48–105) 0.235
Valve dysfunction (n) 42 3 (7.1%) 42 5 (11.9%) 0.457
Diastolic parameters
Peak E velocity (cms
–1) 42 0.76 (0.58–1.06) 41 0.82 (0.58–1.31) 0.302
Peak A velocity (cms
–1) 42 0.59 (0.31–0.99) 41 0.61 (0.35–1.38) 0.097
E/A-ratio 42 1.38 (0.73–2.84) 41 1.35 (0.53–2.30) 0.259
TVI Et (cms
–1)
c 22 12.0 (7–19) 25 10.0 (7–17) 0.002
E/E0c 22 6.2 (3.8–12.4) 25 7.6 (4.1–13.1) 0.002
Blood pressure
d
Systolic (mmHg) 42 129 (107–154) 38 123 (106–153) 0.011
Diastolic (mmHg) 42 74 (58–99) 38 70 (54–106) 0.018
aNumber of patients in which the respective parameters were available.
bWilcoxon
signed-rank test.
c19 paired observations available.
d24 h ambulatory blood pressure
recordings.
Table 1 Characteristics of participating patients with testicular cancer
Number of patients 42
Age at the start of treatment
Median (range) 27 (18–50) years
Interval between echocardiography
Median (range) 10 (6–15) months
Diagnosis (n)
Non-seminoma 40
Extra-gonadal non-seminoma 1
Seminoma 1
Stage of disease(n)
a
Stage II 28
Stage III 3
Stage IV 11
Prognosis category (n)
b
Good 28
Intermediate 14
Poor 0
Treatment (n)
3o r4 BEP
c 41
2 BEP, 1 VIP
d 1
aRoyal Marsden classification.
bAccording to the International Germ Cell Cancer
Collaborative Group (IGCCCG).
cBEP, bleomycin, etoposide, cisplatin; the number of
cycles was on the basis of the prognostic classification.
dVIP, etoposide, ifosfamide,
cisplatin.
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spre-treatment value (242pmoll
–1) was in a patient with a TVI Et
of 7.0cms
–1 before treatment.
Levels of NT-proBNP and D NT-proBNP did not correlate with
the echocardiographic parameters before and after treatment,
and neither correlated with changes in systolic and/or diastolic
parameters.
Cardiovascular risk factors
Before treatment, CRFs of the 42 patients consisted of obesity
(n¼6), smoking (n¼14 current smokers; n¼5 former smokers)
and hypercholesterolaemia (n¼1). The median BMI of the TC
patients was 24.2kgm
–2 (see Table 2). Nine out of 42 patients
(21%) had hypertension on 24h ambulatory BP recordings; 1 out
of 42 patients was on anti-hypertensive medication (b-blocker).
None had diabetes mellitus.
Seven out of 42 control subjects were obese; the median BMI was
25.0kgm
–2(Table 2), which was not different from the TC patients
(P¼0.656). The systolic BP was significantly higher in the patients
(Po0.0001); the diastolic BP was not different (P¼0.237).
At 1 year after treatment, CRF consisted of obesity (n¼8),
smoking (current smokers n¼11) and hypercholesterolaemia
(n¼3). Four out of 38 patients (11%) had hypertension on 24h
BP recordings.
Both systolic and diastolic BP decreased after treatment com-
pared with baseline (see Table 3). The pre-treatment systolic BP
correlated with D TVI (R¼0.67, P¼0.006) and the TVI Et at
baseline (R¼0.63, P¼0.002). E/A-ratio and D E/A-ratio did not
correlate with both systolic and diastolic BP. The E/A-ratio in TC
patients before treatment correlated with the BMI before treatment
(R¼ 0.49, P¼0.001), which was also true for pre-treatment TVI
Et and BMI (R¼ 0.50; P¼0.019). The WMSI before treatment
did not correlate with the BMI.
Smokers had a lower E/A-ratio before treatment (E/A-ratio of
smokers 1.31 (range 0.74–2.42) vs non-smokers 1.56 (0.87–2.41);
P¼0.039). The TVI Et as well as other echocardiographic
parameters, BP and levels of NT-proBNP were not different
between smokers and non-smokers.
Events
Nuver et al described acute cardiovascular events in this patient
group (Nuver et al, 2005b). During treatment, two patients had a
myocardial infarction and three had pulmonary embolisms.
Omission of patients with cardiovascular events from the analyses
did not change the results significantly (data not shown).
DISCUSSION
In this group of TC patients, we observed changes in TVI Et and
E/E0 within 1 year after cisplatin-based chemotherapy, represent-
ing a deterioration of diastolic cardiac function. Furthermore,
serum levels of NT-proBNP increased.
Several authors report changes in cardiovascular status within
years to decades after chemotherapeutic treatment for TC
(Meinardi et al, 2000; Strumberg et al, 2002; Huddart et al, 2003;
van den Belt-Dusebout et al, 2007), but little is known of the early
changes in cardiac function in these patients. Regarding treatment-
related cardiotoxicity from various cancer treatments, it was
recently postulated that diastolic cardiac function deteriorates
before the development of systolic dysfunction (Ewer and Lenihan,
2008). In left ventricular dysfunction of various origins, a deterio-
ration of diastolic function can be present in the absence of systolic
impairment (Lester et al, 2008), and sub-clinical diastolic dysfunc-
tion frequently precedes a drop in systolic parameters (Zile and
Brutsaert, 2002).
Echocardiography is a frequently used method for assessing
cardiac function, which has the advantage that it enables a reliable
estimation of diastolic function by means of more recently
introduced parameters, such as TVI Et and E/E0. Other diastolic
parameters, like the E/A-ratio, are largely dependent on preload
conditions (Hurrell et al, 1997; Sohn et al, 1997), resulting in
significant intra-individual variation.
The TVI Et assesses the velocity of the myocardium at different
angles from the mitral valve, instead of blood-flow velocities, and
is therefore independent of loading conditions (Sohn et al, 1997;
Nikitin and Witte, 2004), resulting in less intra-individual varia-
tion. This parameter is considered an important and reliable early
predictor for the development cardiac dysfunction in other causes
of cardiac disease (Nikitin and Witte, 2004). From several small
studies in adult childhood cancer survivors, it seemed to be a
valuable parameter in defining diastolic (dys-) function (Kapusta
et al, 2001; Brouwer et al, 2006; Tassan-Mangina et al, 2006;
Galderisi et al, 2007). E/E0 is a derivative of TVI Et and the
E velocity, thereby including the end-diastolic left ventricular
filling pressure in addition to myocardial velocities. This para-
meter is currently regarded as a valuable non-invasive method for
diagnosing diastolic heart failure (Paulus et al, 2007). Declines in
diastolic cardiac function are reflected by increases in E/E0 as well
as decreases in TVI Et.
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Figure 2 Serum levels of N-Terminal pro-Brain Natriuretic Peptide
(NT-proBNP) in 32 patients before and after treatment (normal
p14.75pmoll
–1); open circles represent median values. Median NT-
proBNP before treatment 5pmoll
–1 (range o5–242); after treatment
18pmoll
–1 (range o5–114); P¼0.034.
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Figure 1 The tissue velocity imaging of early diastole (TVI Et) in 19
patients before and after chemotherapy; open circles represent median
values. Median TVI Et before treatment 12.0cms
–1 (range 7–19), after
treatment 10.0cms
–1 (range 7–17); P¼0.002.
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patient group corresponded with the same measurements in an
age-matched group of healthy controls. In the patient group, a
correlation existed between age and pre-treatment E/A-ratio, but
not between age and TVI Et or D TVI Et. This is relevant, as ageing
is associated with a physiological decline in diastolic cardiac
function (Galderisi, 2005). An age-dependent decrease in TVI Et
has been shown in healthy controls, but this has only been
evaluated in cohorts with larger differences in age and with longer
time intervals (Wierzbowska-Drabik et al, 2008).
Several CRFs can lead to declines in diastolic function, including
hypertension and obesity (Zile and Brutsaert, 2002). In this
study, the pre-treatment systolic BP correlated with D TVI Et.
Contrarily, the BMI did not correlate with the changes in TVI Et.
The significant decrease in systolic and diastolic BP on the 24h
ambulatory recordings was also found in the larger study
investigating chemotherapy-induced acute cardiovascular toxicity
(Nuver et al, 2005b). The causes for this finding are not known, but
may at least partly be attributed to a relatively high BP before the
start of treatment, which is confirmed by the finding of a higher
systolic BP in the patients compared with the age-matched controls.
This high BP might be because of stress before the initiation of
treatment.
In this study we did not further investigate explanations for this
cardiovascular toxicity. The main causes are thought to be related
to direct damage to cardiomyocytes and/or the extracellular
matrix, as well as sub-clinical vascular injury that induces endo-
thelial dysfunction. Furthermore, the presence of pre-treatment
elevations in BP may have resulted in impaired relaxation of the
left ventricle, thereby leading to diastolic function decline. Of note,
the increase in serum NT-proBNP levels is in accordance with the
picture of cardiac damage.
It is unknown whether a deterioration of diastolic cardiac
function during the first year after chemotherapy for TC
will progress to clinically relevant cardiac disease. It can be
hypothesised that the hearts of these relatively young patients
can compensate for the chemotherapy-induced damage. On
the contrary, they are at increased risk of developing an
unfavourable cardiovascular-risk profile (Meinardi et al, 2000;
Strumberg et al, 2002; Nuver et al, 2005c; Haugnes et al, 2007),
which can contribute to the development of long-term cardiac
failure.
In conclusion, we observed significant changes in TVI Et and
E/E0 within 1 year after cisplatin-based treatment for TC,
indicating a deterioration of diastolic cardiac function. The
prognostic significance of this disturbed diastolic function after
chemotherapy for future cardiovascular morbidity is not clear,
but it might eventually lead to overt cardiac morbidity. Further
longitudinal research in TC survivors is needed to obtain more
insight in sub-clinical changes in cardiac function.
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